Canopy Growth Corp vs Atlassian Corporation PLC — how do they compare? Canopy Growth Corp trades at $1.03 (market cap $421.10M), while Atlassian Corporation PLC trades at $152.21 (market cap $39.10B). The key difference: Atlassian Corporation PLC is far larger — about 92.9× Canopy Growth Corp's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | TEAM | |
|---|---|---|
Market Cap | $421.10M | $39.10B |
Sector | Health | Technology |
52-Week High | $1.92 | $182.36 |
52-Week Low | $0.86 | $57.15 |
Enterprise Value | $378.55M | $39.09B |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $1.02, up 7.13% with a bullish technical signal. The company reported Q1 fiscal 2027 revenue growth of 13% to C$81.2 million and narrowed its EBITDA loss. While revenue trends show stabilization after declining from $520M in 2022 to $269M in 2025, the company continues to post significant net losses with a -222.36% margin. The balance sheet shows improvement with debt-to-asset ratio declining from 53.61% in 2023 to 33.13% in 2025.
CGC presents a high-risk opportunity with potential catalysts from cannabis rescheduling and European expansion. The stock trades below book value (P/B 0.86) but faces substantial execution risks amid persistent losses. Analyst sentiment is mixed with 33% buy ratings, reflecting optimism about restructuring progress versus concerns about profitability timeline.
Atlassian (TEAM) stock trades at $151.87, up 1.88% today and near its 52-week high, reflecting strong momentum after a 35% surge post-Q4 earnings. The company reported 28% revenue growth to $1.77 billion, beating estimates, with cloud revenue accelerating to 31%. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals highlight robust growth amid negative net margins. Analyst sentiment is overwhelmingly positive, with 67% buy ratings and a $161.93 consensus target.
Outlook remains favorable driven by enterprise deal expansion and AI platform adoption, though risks include high valuation multiples (P/S 6.1, EV/EBITDA 184.26) and persistent net losses. Investors should weigh growth prospects against profitability challenges and market volatility. The stock's proximity to all-time highs suggests cautious optimism is warranted.
Trailing returns across standard periods
Latest headlines on both assets
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →